600380.SHG Joincare Pharmaceutical Group Industry Co Ltd
- Market cap
- CNY 19.2B
- P/E
- 17.2x
- P/B
- 1.32x
- ROE
- 8.3%
- Dividend yield
- 2.33%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600380.SHG undervalued?
Graham number600380.SHG trades 0.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Joincare Pharmaceutical Group Industry Co Ltd fundamental analysis
No fundamental analysis for Joincare Pharmaceutical Group Industry Co Ltd yet.
Joincare Pharmaceutical Group Industry Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Joincare Pharmaceutical Group Industry Co Ltd
Joincare Pharmaceutical Group Industry Co.,Ltd. engages in the research, development, production, and sale of pharmaceuticals and health care products in China and internationally. The company offers chemical pharmaceuticals for respiratory, gastroenterology, assisted reproduction, psychiatry, and anti-infection; chemical APIs and intermediates for drugs for humans and veterinary drugs; and traditional Chinese medicine, including cold medicine anti-viral granules and anti-tu…
Full company profileJoincare Pharmaceutical Group Industry Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Joincare Pharmaceutical Group Industry Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.72B | 10.8B | 11.2B | 12.0B | 13.5B | 15.9B | 17.1B | 16.6B | 15.6B | 15.2B | 12.9B |
| Gross Profit | 6.00B | 6.73B | 6.92B | 7.66B | 8.58B | 10.1B | 10.8B | 10.0B | 9.52B | 9.50B | 7.44B |
| Operating Income | 1.05B | 5.87B | 1.59B | 2.19B | 2.97B | 2.98B | 3.48B | 3.51B | 3.62B | 3.19B | 2.65B |
| EBITDA | 1.61B | 1.94B | 1.91B | 2.31B | 2.99B | 3.17B | 3.68B | 3.84B | 3.87B | 4.27B | 2.99B |
| Net Income | 451M | 2.13B | 699M | 894M | 1.12B | 1.33B | 1.50B | 1.44B | 1.39B | 1.34B | 1.18B |
| EPS | 0.26 | 1.36 | 0.43 | 0.46 | 0.57 | 0.69 | 0.79 | 0.76 | 0.74 | 0.73 | 0.65 |
| Balance Sheet | |||||||||||
| Total Assets | 16.1B | 22.2B | 25.0B | 25.4B | 28.2B | 31.1B | 35.7B | 36.4B | 35.7B | 35.4B | 34.7B |
| Total Liabilities | 6.74B | 8.59B | 8.69B | 8.05B | 8.92B | 10.9B | 13.7B | 13.7B | 12.3B | 11.0B | 12.1B |
| Shareholders' Equity | 5.38B | 7.39B | 9.64B | 10.4B | 11.1B | 11.8B | 13.1B | 13.8B | 14.5B | 15.2B | 14.3B |
| Cash & Short-term Investments | 2.95B | 9.07B | 11.5B | 11.2B | 12.3B | 11.9B | 14.9B | 16.2B | 14.9B | 13.6B | 11.8B |
| Total Debt | 1.90B | 2.66B | 3.70B | 2.68B | 2.49B | 3.46B | 5.44B | 5.21B | 4.90B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.64B | 1.87B | 1.83B | 2.31B | 3.02B | 2.56B | 3.98B | 3.93B | 3.64B | 3.89B | - |
| Capital Expenditure | 500M | 481M | 655M | 703M | 830M | 1.52B | 1.15B | 1.13B | 979M | 767M | 782M |
| Free Cash Flow | 1.14B | 1.39B | 1.17B | 1.61B | 2.19B | 1.04B | 2.83B | 2.80B | 2.66B | 3.12B | 2.94B |
| Ratios | |||||||||||
| ROE | 8.4% | 28.9% | 7.3% | 8.6% | 10.1% | 11.2% | 11.5% | 10.5% | 9.5% | 8.8% | 8.3% |
| ROA | 2.8% | 9.6% | 2.8% | 3.5% | 4.0% | 4.3% | 4.2% | 4.0% | 3.9% | 3.8% | 3.4% |
| Net Profit Margin | 4.6% | 19.8% | 6.2% | 7.5% | 8.3% | 8.4% | 8.8% | 8.7% | 8.9% | 8.8% | 9.2% |
| Debt to Equity | 0.35x | 0.36x | 0.38x | 0.26x | 0.22x | 0.29x | 0.41x | 0.38x | 0.34x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Joincare Pharmaceutical Group Industry Co Ltd dividends
- Dividend yield
- 2.33%
- Forward dividend
- 0.93 CNY
- Payout ratio
- 33.5%
- Ex-dividend date
- Oct 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 447M | 0.24 | 33.5% |
| 2024 | CNY 468M | 0.25 | 33.8% |
| 2023 | CNY 337M | 0.18 | 23.3% |
| 2022 | CNY 278M | 0.15 | 18.5% |
| 2021 | CNY 289M | 0.15 | 21.7% |
| 2020 | CNY 308M | 0.16 | 27.5% |
| 2019 | CNY 310M | 0.16 | 34.7% |
| 2018 | CNY 447M | 0.27 | 63.8% |
| 2017 | CNY 369M | 0.24 | 17.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 12:10 on May 16, 2012.
Who owns Joincare Pharmaceutical Group Industry Co Ltd
- Insiders 53.36%
- Institutions 5.31%
- Public & others 41.34%
- Shares outstanding 1.83B
- Free float 886M
Joincare Pharmaceutical Group Industry Co Ltd company profile
- Company name
- Joincare Pharmaceutical Group Industry Co Ltd
- Ticker
- 600380.SHG
- ISIN
- CNE000001816
- Exchange
- Shanghai Stock Exchange
- Listed since
- May 9, 2001
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 13,575
- Fiscal year end
- December
- Address
- Joincare Pharmaceutical Group Building, Shenzhen, China, 518057
- Phone
- 86 75 8625 2368
- Website
- joincare.com
About Joincare Pharmaceutical Group Industry Co Ltd
Joincare Pharmaceutical Group Industry Co.,Ltd. engages in the research, development, production, and sale of pharmaceuticals and health care products in China and internationally. The company offers chemical pharmaceuticals for respiratory, gastroenterology, assisted reproduction, psychiatry, and anti-infection; chemical APIs and intermediates for drugs for humans and veterinary drugs; and traditional Chinese medicine, including cold medicine anti-viral granules and anti-tumor medicine. It also provides diagnostic reagents and equipment, such as mycoplasma pneumoniae IgM antibody test and antinuclear antibody test kit; OTC products which includes Taitai and Jingxin oral liquid, Eagle's American ginseng tea, and YikeTie; and biologics comprising tocilizumab and mouse nerve growth factor injection. The company was founded in 1992 and is headquartered in Shenzhen, China.
Joincare Pharmaceutical Group Industry Co Ltd management
8- Mr. Nanqi LinPresident & Director · born 1982
- Mr. Qingfeng QiuVP, CFO & Director · born 1971
- Mr. Zhiwei XingVP & Director · born 1986
- Mr. Yifan ZhuBoard Secretary · born 1987
- Mr. Leiming ZhangVice President · born 1983
- Ms. Yanmei DuVice President · born 1987
- Mr. Tingke TangVice President · born 1985
- Ms. Chenlu GuoHead of Accounting Department